Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

References

• Cassileth P.A., Harrington D.P., Appelbaum F.R., Lazarus H.M., Rowe J.M., Paietta E., Willman C., Hurd D.D., Bennett J.M., Blume K.G., Head D.R., Wiernik P.H. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339: 1649–1656
   Google Scholar
• Wiernik PH., Banks PL., Case D.C., Arlin Z.A., Per-Iman P.O., Todd M.B., Ritch PS., Enck R.E., Weit-Berg A.B. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79: 313–319
   Google Scholar
• Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Schiller G.J. Treatment of resistant disease. Leukemia 1998; 12: S20–S24
   PubMed Web of Science ®Google Scholar
• Reece D.E., Elmongy M.B., Barnett M.J., Klingemann H.G., Shepeherd J.D., Phillips G.L. Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor prognosis myeloid leukemias. Cancer Invest. 1993; 11: 509–516
   Google Scholar
• Keating M.J., Kantarjian H., Smith T.L., Estey E., Walters R., Andersson B., Beran M., McCredie K.B., Freireich E.J. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989; 7: 1071–1080
   Google Scholar
• Saven A., Piro L.D. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 1993; ll: 109–114
   Web of Science ®Google Scholar
• Keating M.J., McLaughlin P., Plunkett W., Robertson L.E., O'Brien S., Gandhi V., Gregoire V., Yang L., Cabanillas F. Fludarabine - present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 1994; 5: S79–S83
   PubMed Web of Science ®Google Scholar
• Warrell R., Berman E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986; 4: 74–79
   Google Scholar
• Estey E., Plunkett W., Gandhi V., Rios M.B., Kantarjian H., Keating M. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymph. 1993; 9: 343–350
   Web of Science ®Google Scholar
• Kornblau S.M., Gandhi V, Andreeff H.M., Beran M., Kantarjian H.M., Roller C.A., O'Brien S., Plunkett W, Estey E. Clinical and laboratory studies of 2-chloro-deoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996; 10: 1563–1569
   Google Scholar
• Estey E., Thall P., Andreeff M. Use of G-CSF before, during and after fludarabine plus Ara-C induction therapy of newly diagnosed AML or MDS: comparison with fludarabine + Ara-C without G-CSF. J Clin Oncol. 1994; 4: 671–678
   Google Scholar
• Visani G., Tosi P., Zinzani P.L. FLAG (fludarabine + high dose cytarabine + G-CSF) an effective and tolerable protocol for the treatment of “poor risk” acute myeloid leukemias. Leukemia. 1994; 8: 1842–1846
   Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Gal-Ton D.A., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620–625
   Google Scholar
• Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield CD., Brunning R., Gale R.P, Grever M.R., Keating M.J. Report of the National Cancer Institute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8: 813–819
   Google Scholar
• Preisler H.D., Gopal V. Regrowth resistance in leukemia and lymphoma, the need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res. 1994; 18: 149–160
   Google Scholar
• Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis TE., McFadden E.T., Carbone P.P. Toxicity and response criteria for the Eastern Cooperative Oncology Group. Am J Clin. Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Montillo M., Mirto S., Petti M.C., Latagliata R., Magrin S., Pinto A., Zagonel V., Mele G., Tedeschi A., Fer-Rara F. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998; 58: 105–109
   Google Scholar
• Fleischhack G., Hasan C., Graf N., Mann G., Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF) an effective remission -induction therapy for poor -prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br. J. Haematol, 102: 647–655
   PubMed Web of Science ®Google Scholar
• Santana V.M., Hurwitz C.A., Blakley R.L., Crom W.R., Luo X., Roberts W.M., Ribeiro R., Mahmoud H., Krauce R.A. Complete hematologic remissions induced by 2-Chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84: 1237–1242
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Keating M.J., Chucrallah A., Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia pharmacokinetic, pharmacodynamic and molecular interactions. Blood. 1996; 87: 256–264
   Google Scholar
• Clavio M., Carrara P., Miglino M., Pierri J., Canepa L., Balleari E., Gatti A.M., Cerri R., Celesti L., Vallebella E., Sessarego M., Patrone F., Ghio R., Gobbi M. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Hae-matologica 1996; 81: 513–520
   PubMedGoogle Scholar
• Parker J.E., Pagliuca A., Mijovic A., Cullis J.O., Czepulkowski B., Rassam S.M., Samaratunga J.R., Grace R., Gover P.A., Mufti G.J. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol. 1997; 99: 939–944
   Google Scholar
• Van Den Neste E., Martiat P., Mineur P., Dellanoy A., Doyen C., Zenebergh A., Michaux J.L., Ferrant A. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann Hematol. 1998; 76: 19–23
   Google Scholar
• Visani G., Lemoli R.M., Tosi P., Martinelli G., Testoni N., Ricci P., Pccaluga P.P., Pastano R., Leopardi G., Dizdari A., Motta M.R., Rizzi S., Tura S. Fludarab-ine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br. J. Haematol. 1999; 105: 775–779
   Google Scholar